MX2013014566A - Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide. - Google Patents

Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide.

Info

Publication number
MX2013014566A
MX2013014566A MX2013014566A MX2013014566A MX2013014566A MX 2013014566 A MX2013014566 A MX 2013014566A MX 2013014566 A MX2013014566 A MX 2013014566A MX 2013014566 A MX2013014566 A MX 2013014566A MX 2013014566 A MX2013014566 A MX 2013014566A
Authority
MX
Mexico
Prior art keywords
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
receptor mediated
Prior art date
Application number
MX2013014566A
Other languages
English (en)
Inventor
Helena Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2013014566A publication Critical patent/MX2013014566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofen il) indazol-5-il] oxi-1-(3-metoxifenil)propan-2-illacetamida, procesos para obtenerlas, intermedios farmacéuticos empleados en su manufactura, composiciones farmacéuticas que las contienen y su uso en tratamientos médicos.
MX2013014566A 2011-06-29 2012-06-27 Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide. MX2013014566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
MX2013014566A true MX2013014566A (es) 2014-09-25

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014566A MX2013014566A (es) 2011-06-29 2012-06-27 Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide.

Country Status (16)

Country Link
EP (1) EP2726464A1 (es)
JP (1) JP2014527955A (es)
KR (1) KR20140036230A (es)
CN (1) CN103814015A (es)
AR (1) AR086818A1 (es)
AU (1) AU2012277514A1 (es)
BR (1) BR112013031759A2 (es)
CA (1) CA2839398A1 (es)
IN (1) IN2014MN00023A (es)
MX (1) MX2013014566A (es)
RU (1) RU2013153466A (es)
SG (1) SG195309A1 (es)
TW (1) TW201305115A (es)
UY (1) UY34170A (es)
WO (1) WO2013001294A1 (es)
ZA (1) ZA201309480B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
WO2022114105A1 (ja) * 2020-11-27 2022-06-02 ミライラボバイオサイエンス株式会社 高純度βニコチンアミドモノヌクレオチド（ＮＭＮ）及びその製造方法
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
ES2535979T3 (es) 2010-07-21 2015-05-19 Astrazeneca Ab Inhalador
CN103118727B (zh) 2010-07-21 2015-11-25 阿斯利康(瑞典)有限公司 吸入器

Also Published As

Publication number Publication date
CN103814015A (zh) 2014-05-21
EP2726464A1 (en) 2014-05-07
CA2839398A1 (en) 2013-01-03
UY34170A (es) 2013-01-31
WO2013001294A1 (en) 2013-01-03
SG195309A1 (en) 2013-12-30
KR20140036230A (ko) 2014-03-25
RU2013153466A (ru) 2015-08-10
TW201305115A (zh) 2013-02-01
BR112013031759A2 (pt) 2016-12-13
AU2012277514A1 (en) 2014-01-09
ZA201309480B (en) 2015-10-28
JP2014527955A (ja) 2014-10-23
AR086818A1 (es) 2014-01-22
IN2014MN00023A (es) 2015-06-12

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
GEP20156339B (en) New co-crystals of agomelatine, process for their preparation and pharmaceutical compositions containing them
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
MY150931A (en) Substituted oxazolidinones and their use
PH12017500595B1 (en) Aldosterone synthase inhibitors
MX2013014566A (es) Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide.
IN2013DN02555A (es)
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
UA112981C2 (uk) Варіант людського gdnf
IN2013MU02059A (es)
CL2009000118A1 (es) Compuestos derivados de carboxamida o carboxatioamida azabiciclica, moduladores de trv1; composicion farmaceutica que los contiene; proceso de preparacion de los compuestos e intermediarios; y uso en el tratamiento del dolor, inflamacion, trastornos metabolico, entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal